Trump Didn’t Legalize Weed — Here’s What the EO Actually Does

Quick Overview

The executive order signed by the President on December 18, 2025, does not legalize marijuana federally; instead, it directs the rescheduling of marijuana from Schedule I to Schedule III and facilitates increased research into medical marijuana and CBD, allowing access to research facilities and clinical trials for conditions like chronic pain and nausea.

Key Points: The Executive Order (EO) dated December 18, 2025, directs the rescheduling of marijuana from Schedule I to Schedule III, which removes one major barrier to research. The EO specifically supports increased research on medical marijuana and CBD for conditions like anorexia, nausea, vomiting, and pain, noting chronic pain affects nearly 1 in 4 US adults. The action allows research facilities and universities access to research materials to conduct clinical trials. The speakers note that while this is a significant policy shift since the War on Drugs began, it does not federally legalize recreational marijuana or decriminalize it. H.R. 3492, the "Protect Children's Innocence Act," sponsored by Rep. Marjorie Taylor Greene, passed the House with a vote of 216 to 111, but it is a separate piece of legislation that criminalizes gender-affirming care for minors. The speakers express concern that the bill regarding gender-affirming care is moving forward, suggesting that common law principles regarding age of consent for permanent procedures (like irreversible surgery) should apply.

Context: The video features two hosts from the Impact Theory podcast discussing a recent White House Executive Order concerning medical marijuana and cannabidiol (CBD) research, dated December 18, 2025. Simultaneously, one speaker brings up a separate, controversial piece of legislation, H.R. 3492, the "Protect Children's Innocence Act," which passed the House and aims to criminalize gender-affirming care for minors, contrasting the two legislative actions.

Detailed Analysis

The discussion centers on a December 18, 2025, Executive Order aimed at increasing research into medical marijuana and CBD. The EO orders the rescheduling of marijuana from Schedule I to Schedule III, which significantly eases regulatory hurdles for research. This change grants access to research facilities and universities to conduct clinical trials for treating conditions such as anorexia, nausea, vomiting, and pain. The speakers emphasize that this EO is a major policy shift but does not equate to federal legalization or decriminalization of recreational use. Separately, the hosts discuss H.R. 3492, the "Protect Children's Innocence Act," which passed the House 216 to 111. They view this bill, which seeks to criminalize gender-affirming care for minors, as a significant and potentially problematic legislative move, arguing that common law principles should prevent irreversible procedures for those not considered capable of giving full consent.